Lavender.

Lavender's linalool and linalyl acetate reduce presynaptic glutamate release through voltage-gated calcium channels, while lemon balm's rosmarinic acid slows GABA transaminase and keeps GABA in the synapse. The two act on opposite sides of the excitatory and inhibitory balance.

Valerenic acid is a positive modulator at the GABA-A receptor while lavender works upstream on presynaptic calcium entry. The pairing is conventional in evening botanical blends because the mechanisms do not duplicate.

Passionflower flavonoids act at the benzodiazepine site of GABA-A, adding inhibitory tone where lavender reduces excitatory release. Their effects on relaxation are additive.

Apigenin from chamomile binds the GABA-A benzodiazepine site, and lavender's terpenes damp glutamate release presynaptically. Two different points on the same circuit.

Hops bitter acids act on GABA-A and melatonin signalling and are traditionally combined with valerian and lavender in sleep preparations. The combination is one of the oldest in European herbal formulation.

Theanine raises alpha wave activity and modestly blocks glutamate binding at AMPA and kainate sites, a different route from lavender's calcium channel effect. Both support calm without sedation as the primary action.

Melatonin signals circadian timing through MT1 and MT2 receptors while lavender reduces arousal through neurotransmitter release. Timing and arousal are separate levers on the same outcome.

Magnesium sits in the NMDA receptor channel and blocks excitatory calcium entry, and the glycine carrier is itself an inhibitory transmitter. Lavender lowers glutamate release upstream of the same receptor.

Lavender's terpenes lower excitatory transmitter release into a synapse where GABA is the main inhibitory signal. The two push the excitation and inhibition balance in the same direction.

Honokiol is a positive modulator at GABA-A at a site distinct from the benzodiazepine pocket. Combined with lavender's presynaptic effect the calming action is additive.

California poppy alkaloids act on GABA-A binding and are conventionally combined with lavender in evening preparations. The pairing is long-standing European formulation practice.

Caffeine blocks adenosine A1 and A2A receptors and raises central arousal, the opposite of what lavender's reduction in excitatory transmitter release produces. Taken in the same window each blunts what the other is there to do.

A standardised lavender oil preparation was among the agents assessed in a systematic review and meta-analysis of interventions for milder low mood. Saffron extract is studied on overlapping self-report measures. The two have not been given together in any study, so the pairing rests on category overlap.

Glycine acts at its own inhibitory receptor and as a co-agonist at the NMDA receptor, which is settled receptor biochemistry. Lavender preparations appear in the same evening formulas. Nothing has tested the combination, and the shared placement is a formulation habit rather than evidence.

Lavandula species carry apigenin and luteolin derivatives in their flavonoid fraction alongside the volatile terpenes. Adding an apigenin ingredient reinforces a class already present in the plant. This is compositional logic, and the essential oil preparations that carry most of the human research are largely stripped of the flavonoid fraction by distillation.

Lavender oil is dominated by linalool and linalyl acetate, and rosemary oil by 1,8-cineole and camphor, all monoterpenoids from the same biosynthetic route. Studies of Lamiaceae aromatic oil blends have been run in production animals, where the oils are handled as one class. Combining them raises total volatile terpene load, which is the practical point for a formulator.

Menthol-dominant peppermint oil and linalool-dominant lavender oil are both volatile monoterpene preparations, and blends of them are conventional in aromatic products. The combined terpene load is what determines gastric tolerability of an oral oil capsule. This is preparation chemistry rather than a studied interaction.

Thymol-rich thyme oil and linalool-rich lavender oil are handled together as aromatic Lamiaceae oils in feed-additive research, where the class effect on gut microbiota and oxidative stability is the readout. That research is in production animals and does not describe what either does in a person. The chemistry overlap itself is established.

Oregano oil's phenolic monoterpenes are considerably more irritant to mucosa than lavender's linalool and linalyl acetate, so blending them changes the tolerability profile of the whole preparation. Feed-additive studies handle these oils as one aromatic class in poultry and ruminants. Nothing here describes a human effect.

Ashwagandha is studied for effects on stress-axis measures and self-reported stress, while a standardised lavender oil preparation appears among interventions assessed for milder low mood. The combination has not been tested. A formula carrying both is stacking two separate literatures.

Both appear in the same class of formula and each has its own separate human research. No study has given them together. The pairing is formulation convention and should not be read as a measured effect.

5-hydroxytryptophan is decarboxylated directly to serotonin, bypassing the rate-limiting tryptophan hydroxylase step, which is textbook biochemistry. Lavender preparations sit in the same evening formulas. Anyone already taking a serotonergic prescription should discuss adding either with a prescriber, since the combined effect on drowsiness and on serotonergic tone is not something a label can predict.

Tryptophan is the dietary precursor for serotonin synthesis via tryptophan hydroxylase and then decarboxylation, and it competes with other large neutral amino acids for transport across the blood brain barrier. Lavender preparations are formulated into the same evening products. The combination has not been studied and the additive effect on drowsiness is the practical caution.

Pyridoxal 5-phosphate is the cofactor for the decarboxylase that converts 5-hydroxytryptophan to serotonin and L-DOPA to dopamine. That is settled biochemistry and needs no citation. Its appearance beside lavender in evening formulas is cofactor logic, not a tested pairing.

St John's wort induces CYP3A4 and P-glycoprotein, which changes the handling of many co-taken substances and is one of the better characterised botanical interactions in pharmacology. Combining it with a lavender preparation also stacks two agents used for subjective calm. Anyone on prescription medicine should raise this pairing with a prescriber before starting either.

Bacopa's triterpenoid saponins and lavender's monoterpenes are unrelated chemistry examined in overlapping research areas. Formulas pair them for that reason. The combination has no study behind it.

Linalool and linalyl acetate oxidise on exposure to air and light, and the oxidation products are the fraction associated with skin sensitisation in the fragrance literature. Tocopherol is added to volatile oil preparations as an antioxidant that slows that chemistry. Work on encapsulated lavender oil in feed has used oxidative stability as its primary readout. The role here is stabilising the preparation, not a physiological pairing.

Neat lavender essential oil is too concentrated for oral capsule dosing and is routinely diluted into a carrier lipid so the dose can be measured and the mucosal exposure reduced. Medium-chain triglycerides are chosen because they are liquid at room temperature and stable to oxidation. This is a delivery decision and does not change what the oil does.